Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Copenhagen, Denmark

Valiltramiprosate Shows Promise as an Oral Potentially Disease-Modifying Agent that can Slow Alzheimer’s Disease Based on Clinical Results, MRI Data, and Fluid Biomarkers in APOE4/4 MCI Patients Two Oral Presentations and Six Posters Highlight Consistent Effects of Oral Valiltramiprosate on Brain Volume, Microstructural Integrity, Neurodegeneration, Systems Modeling, and Long-Term Clinical Stability Valiltramiprosate Designed to […] The post Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Copenhagen